Openbookopenbook
Equity
Kyntra Bio, Inc.(KYNB)
USD --+0.00%
Reward29Low
Risk77High
📊75%Data
Strong 2599% profit margin · Revenue growing 775% YoY
KYNB
+0.0 · +0.00%
USD · NASDAQ
Kyntra Bio, Inc. | Healthcare
Capital Destroyer
Market Cap:29.41M
ℹ️
Reward Rating
29
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
77
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on KYNB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $43.00.

What is Kyntra Bio, Inc.?

, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

KYNB · Verdict

Limited reward · high risk

KYNB has limited near-term tailwinds — cash flow and growth weigh on the model output.

Based on 88% data coverage

KYNB · Verdict

What’s working & what to watch

Watchouts 5

  • Cash flow6/100

    -467% free-cash-flow margin

  • Growth14/100

    Rev -49.9% CAGR · earnings -45.3%

  • Balance sheet18/100

    Current ratio 1.47

  • Profitability24/100

    -161% net margin · 0% ROE

  • Valuation41/100

    P/E 61.3×

Model-based scoring. For information only — not financial advice.

What is Kyntra Bio, Inc.?

, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 29.41M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (29)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap29.41M
P/E RatioN/A
Dividend YieldN/A
52 Week High12.6
52 Week Low4.85
Last AnnualDecember
IPO Date11/14/2014
IncorporatedUSA
Shares Outstanding4M
No. of Employees225
IndustryBiotechnology
ExchangeNASDAQ
Beta0.831
CurrencyUSD
Websitewww.kyntrabio.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.